top of page

Search Results

Search results for "Dopamine receptor D3"

Results found for "Dopamine receptor D3"

  • đź“° GPCR Weekly News, March 18 to 24, 2024

    24th, 2024 GPCR Activation and Signaling Calcium-Driven In Silico Inactivation of a Human Olfactory Receptor Deciphering the role of glycosaminoglycans in GPCR signaling G protein-coupled receptor-mediated autophagy vivo through inhibiting CREB-ALK5-mediated endothelial to mesenchymal transition Role of pH-sensing receptors endogenous G proteins on endosomes and other organelles Reviews, GPCRs, and more G protein-coupled receptor Structural and Molecular Insights into GPCR Function Structural bioinformatics studies of serotonin, dopamine

  • đź“° GPCR Weekly News, May 22 to 28, 2023

    Bioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist. Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Structural genomics of the human dopamine receptor system Structural Insights into Molecular Recognition and Receptor Activation in Chemokine–Chemokine Receptor Complexes Industry News Mavorixafor reduces

  • đź“° GPCR Weekly News, August 28 to September 3, 2023

    Endocrinology, and Taste Cholecystokinin-A Signaling Regulates Automaticity of Pacemaker Cardiomyocytes Dopamine Receptor D1 Is Exempt from Transforming Growth Factor β-Mediated Antifibrotic G Protein-Coupled Receptor A case for (mutant) G protein-coupled receptors Reviews, GPCRs, and more RGS2 and female common diseases single particle cryo-EM analysis Structure-based drug discovery of a corticotropin-releasing hormone receptor X-ray free-electron laser Structural insight into the selective agonist ST1936 binding of serotonin receptor

  • đź“° GPCR Weekly News, May 29 to June 4, 2023

    Tagged for arrest: 'Barcode' determines receptor's fate. Our next Dr. How can we improve the measurement of receptor signaling bias? New paradigms in purinergic receptor ligand discovery. The role of G protein conformation in receptor-G protein selectivity. Computational insights into ligand-induced G protein and β-arrestin signaling of the dopamine D1 receptor

  • VAMP2: a crucial player in the delivery of MOR to the synapse

    Transporting Protein-coupled receptors (GPCRs) to the synapse, where they are involved in neurotransmission Some studies have suggested that VAMP2 may be involved in regulating dopamine D2 receptor signaling by controlling the trafficking of the receptor to the cell surface. receptor (MOR) [1,6,7]. Phosphorylation state of muopioid receptor determines the alternative recycling of receptor via Rab4

  • đź“° GPCR Weekly News, March 27 to April 4, 2023

    Negative allosteric modulation of the glucagon receptor by RAMP2. Itch receptor MRGPRX4 interacts with the receptor activity-modifying proteins (RAMPs). Gαi-derived peptide binds the µ-opioid receptor. Dopamine Receptor D1R and D3R and GRK4 Interaction in Hypertension. Structural insights into constitutive activity of 5-HT6 receptor.

  • đź“° GPCR Weekly News

    Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic targets Constitutive activity of the dopamine receptor D5R, highly expressed in CA1 hippocampal neurons, selectively reduces CaV 3.2 and CaV 3.3 currents Mass Spectrometry Reveals Activity-Modifying Phosphorylation Barcode in a Class C G Protein-Coupled Receptor Molecular Insights into GPCR Function Synergistic and Competitive Lipid Interactions in the Serotonin 1A Receptor Current Technologies To Understand G-Protein-Coupled Receptor Molecular Pharmacology.

  • đź“° GPCR Weekly News, April 22 to 28, 2024

    GPCR News from April 22nd to 28th, 2024 Adhesion GPCRs Dysfunction of the adhesion G protein-coupled receptor peptide signaling durations and the structural determinants thereof Ubiquitin-driven G Protein-Coupled Receptor Methods & Updates in GPCR Research Single-chain fluorescent integrators for mapping G-protein-coupled receptor The nematode-trapping fungus Arthrobotrys oligospora detects prey pheromones via G protein-coupled receptors by Class A GPCRs Industry News Introducing Big Sky BacMam Chemical tool illuminates pathways used by dopamine

  • đź“° GPCR Weekly News, January 29 to February 4, 2024

    of Clostridioides difficile toxin B and FZD7 Loss-of-function of GNAL dystonia gene impairs striatal dopamine receptors-mediated adenylyl cyclase/ cyclic AMP signaling pathway The non-nutritive sweetener sucralose increases β-arrestin signaling at the constitutively active orphan G protein-coupled receptor GPR52 capromorelin in veterinary medicine GPCRs in Cardiology, Endocrinology, and Taste The role of P2Y6 receptor in the pathogenesis of cardiovascular and inflammatory diseases β-adrenergic receptor signaling mediated

  • When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue

    Could they map receptor heterogeneity across the islet? Could they quantify plasma membrane vs. intracellular receptor pools? The tools didn’t simply visualize receptors. mapping Super-resolution imaging of receptor nanodomains AI-assisted probe design Multi-receptor visualization Not one receptor at a time. Not one color. Not one imaging depth.

  • đź“° GPCR Weekly News, May 1 to 7, 2023

    GPCR Activation and Signaling Constitutive activity of the dopamine (D5 ) receptor, highly expressed Cholesterol Biases the Conformational Landscape of the Chemokine Receptor CCR3: A MAS SSNMR-Filtered intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin2 G protein-coupled receptor GPCRs in Neuroscience GPCR interactions involving metabotropic glutamate receptors and their relevance G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.

  • Ono Enters into Collaboration Agreement with Domain Therapeutics and UniversitĂ© de MontrĂ©al for ...

    April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal and CEO: Gyo Sagara; “Ono”) today announced that it has newly signed a collaboration agreement with Domain (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM ”), to discover novel small molecules targeting G-Protein Coupled Receptors (GPCRs) in a metabolic disease

  • From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit

    Watch Episode 167 What started with a single receptor became a toolset for an entire superfamily. Tom Sakmar didn’t set out to map GPCR-RAMP interactions across hundreds of receptors. began with a phone call (from Bruce Merrifield, no less) encouraging Sakmar to work on the glucagon receptor A Long-Term Obsession, Reframed Sakmar’s lab had been focused on the secretin receptor family  for decades It was graduate student Emily Lorenzen  who helped frame the next step: stop studying one receptor at

  • Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did

    High-throughput screening for receptor ligands was booming, and Sokhom was at the center of it. exploring signaling bias, and building a robust knowledge base in one of the most pharmacologically diverse receptor A Career Built on Consistency From CGRP receptor antagonists at BMS to opioid receptor research at Alkermes short-term thinkers often miss. _______________ Keyword Cloud: GPCR drug discovery , G protein-coupled receptors

  • Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling

    G protein-coupled receptors (GPCRs) are integral membrane proteins crucial for sensing extracellular These receptors initiate intracellular signaling cascades upon activation, ultimately regulating a myriad Gilman, A.G., G proteins: transducers of receptor-generated signals.  Zhao, P., et al., Activation of the GLP-1 receptor by a non-peptidic agonist.  Galés, C., et al., Real-time monitoring of receptor and G-protein interactions in living cells. 

  • Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids

    The cannabinoid receptor type 2 (CB2R) has emerged as a compelling target across inflammation, immune Subcellular membrane mixtures, altered receptor conformations, and non-specific interactions introduce By quantifying ligand–receptor interactions directly in intact cells, HCS allows researchers to observe In a recent collaborative study, 16 synthetic cannabinoid receptor agonists (SCRAs) were evaluated using Because imaging is captured across thousands of intact cells, each measurement incorporates receptor

  • Radioligands vs. Fluorescent Ligands: Binding Assays

    Understanding receptor-ligand interaction is key in drug discovery and biomedical research. Besides binding assays, they can also be used to study receptor density, binding sites and ligand kinetics interactions, particularly in pharmacokinetic and receptor occupancy studies. They are useful tools to visualize receptors in native or transfected cells, whether living or fixed. Probing the pharmacology of G protein-coupled receptors with fluorescent ligands.

  • Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024

    Azietaku , our great contributor, for his article Class B1 GPCR Dimerization: Unveiling Its Role in Receptor variant in RGS18 candidate for a familial mild bleeding syndrome Fusarium graminearum Ste2 and Ste3 Receptors Heterodimerization when Expressed Heterologously in Saccharomyces cerevisiae The beta 2 adrenergic receptor Neuronal Precursor Cells Derived from Patients Diagnosed with Schizophrenia Sphingosine 1-phosphate receptor the CaSR gene Reviews, GPCRs, and more Insight into structural properties of viral G protein-coupled receptors

  • Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

    March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology

  • Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery

    Pharmacology isn’t only about ligands, receptors, and downstream G protein signaling—it’s also about In this course, you’ll gain: ✅ How assay volume control  alters receptor sensitivity and what that By modulating receptor expression or sensitivity, we can shift the “lens” through which drug activity Why System Sensitivity Matters Consider the signaling cascade: ligand binds receptor, receptor couples Think of it this way: most receptors behave like switches—they stay off until flipped.

  • Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls

    Running total and protected curves simultaneously is essential to reveal true receptor binding. After a ligand binds, the receptor may transition further—often via G protein coupling. This is not receptor heterogeneity—it is a collapsed two-stage system. When G proteins are abundant, curves look clean because every receptor–ligand complex can couple. Changing receptor expression or G protein levels does not  remove curve heterogeneity.

  • Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!

    Kotliar , Thomas Sakmar , et al. for their study on Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins Molecular mechanism of bitter taste receptor agonist-mediated relaxation Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators GPCRs in Oncology and Immunology G protein-coupled receptor-mediated signaling of immunomodulation variants and human genetic disease Advances in yeast synthetic biology for human G protein-coupled receptor

  • A2A Fluorescent Competitive Binding: Advancing NanoBRET® Target Engagement for GPCR Drug Discovery

    The A2A adenosine receptor (A2AAR) is one of four adenosine receptor subtypes expressed in the human Saturation binding experiments on NanoLuc®-tagged A2A receptors. Adenosine Receptors and Their Ligands. Naunyn-Schmied. Arch. Introduction to Adenosine Receptors as Therapeutic Targets. In Adenosine Receptors in Health and Disease; Wilson, C. N., Mustafa, S.

  • Mapping Motion: Intermediate States, Deorphanization & Discovery

    We’re also spotlighting breakthroughs that challenge dogma and deepen our view of receptor dynamics, from the surprising discovery that β-arrestin can bind GPCRs without receptor activation, to visualizing A new cell-based tool detects receptor activity and reveals endogenous ligands.   A powerful three-color approach captures dynamic receptor states in real time. Whether you're decoding a hidden receptor state or hunting for the next orphan GPCR ligand, we're here

  • Ode to GPCRs

    to nicotinic acetylcholine receptors and muscarinic acetylcholine receptors.[18] The 1971 Nobel Prize on signal transduction in the nervous system.[48–54] Carlsson won the prize for his discovery that dopamine Dopamine exerts its action in the human nervous system via dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). for his contributions to the elucidation of the signaling pathways by which neurotransmitters such as dopamine

  • Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies

    The central role of GPCRs in Neurological Disorders GPCRs are the largest family of membrane receptors One of the biggest hurdles is the understanding and correct targeting of the different receptor subtypes GPCR signaling: (A) an orthosteric ligand (orange) binds an inactive GPCR, the β2 adrenergic receptor Orphan G protein-coupled receptors: The role in CNS disorders . A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.

  • Antibodies That Don’t Block, They Activate: A New Angle on Autoimmunity and GPCRs

    Watch Episode 167 Some GPCR-targeting antibodies don’t inhibit receptors. They activate them. Tom Sakmar points to a largely overlooked mechanism  in disease: autoantibodies that don’t block receptors “Some of these antibodies actually activate the receptor and cause pathological signaling.” — Tom Sakmar Luminex assay , researchers can now: Screen patient samples for GPCR autoantibodies Identify which receptor

  • đź“° GPCR Weekly News, July 3 to 9, 2023

    GPCR Activation and Signaling G protein activation via chemokine (C-X-C motif) receptor 4 and α1b -adrenoceptor The G protein-coupled receptor GPRC5C is a saccharide sensor with a novel "off" response. Past, present, and future of tools for dopamine detection.

  • The Five Traps of Ignoring Kinetics

    offset rate, using rapid calcium assays Potency Is a Ratio of Rates Two ligands compete for the same receptor And this texture matters; kinetics have separated safe dopamine antagonists from those with extrapyramidal monophasic curves, you’ll see biphasic signatures or sequential shifts—first cholinesterase inhibition, then receptor

  • Dr. GPCR Updates

    The goal is to accelerate receptor-targeted discovery. It highlights its journey from one receptor to a cross-family toolkit. Hear from Drs. GPR45 steps up: A previously orphan receptor emerges as a powerful target for appetite and obesity control

bottom of page